Literature DB >> 14746353

Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness.

Marian I Butterfield1, Hayden B Bosworth, Karen M Stechuchak, Richard Frothingham, Lori A Bastian, Keith G Meador, Marvin Swartz, Ron D Horner.   

Abstract

Racial differences in the seroprevalence of and risks for hepatitis B (HBV) and hepatitis C (HCV) were examined in military veterans with severe mental illnesses (SMI). Participants (376; 155 Caucasian, 221 African American) were inpatients at a Veterans Affairs (VA) psychiatric unit in Durham, N.C., from 1998 to 2000. Prevalence rates of HBV and HCV were 21.3% and 18.9%, respectively. African Americans had a higher HBV seroprevalence than did Caucasians: 27.6% versus 12.3%; odds ratio (OR) 2.73; 95% confidence interval (CI)=1.55, 4.79. Although not statistically significant, HCV seroprevalence was also higher for African Americans than it was for Caucasians: 21.3% versus 15.5%; OR=1.47; 95% CI=0.86, 2.53. No racial difference was observed for injection drug use (IDU), the strongest risk indicator for both HBV and HCV. Multivariable analyses indicated that African-American race, IDU, and multiple sex partners in the past six months were related to an increased risk of HBV, whereas IDU and smoking crack cocaine were both independently related to an increased risk of HCV. Thus, veterans with SMI--particularly African-American veterans--have high rates of HBV and HCV infection. African-American veterans have significantly higher rates of HBV than do Caucasian veterans, which persist after controlling for prominent risk behaviors.

Entities:  

Mesh:

Year:  2004        PMID: 14746353      PMCID: PMC2594764     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  49 in total

1.  Racial disparities in antipsychotic prescription patterns for patients with schizophrenia.

Authors:  Eri Kuno; Aileen B Rothbard
Journal:  Am J Psychiatry       Date:  2002-04       Impact factor: 18.112

2.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

3.  A case of interferon alpha-induced manic psychosis in chronic hepatitis C.

Authors:  A Kanno; M Yamada; M Abe; Y Okamoto
Journal:  Tohoku J Exp Med       Date:  1999-01       Impact factor: 1.848

4.  Assessment of HIV risk.

Authors:  M C Chawarski; J Pakes; R S Schottenfeld
Journal:  J Addict Dis       Date:  1998

5.  Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.

Authors:  Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

6.  Emotional distress in chronic hepatitis C patients not receiving antiviral therapy.

Authors:  Robert J Fontana; Khozema B Hussain; Steven M Schwartz; Cheryl A Moyer; Grace L Su; Anna S F Lok
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

7.  An open-label trial of citalopram for major depression in patients with hepatitis C.

Authors:  Ondria C Gleason; William R Yates; M Daniel Isbell; Michelle A Philipsen
Journal:  J Clin Psychiatry       Date:  2002-03       Impact factor: 4.384

8.  Cocaine use and characteristics of young adult users from 1987 to 1992: the CARDIA Study. Coronary Artery Risk Development in Young Adults.

Authors:  B L Braun; D Murray; P Hannan; S Sidney; C Le
Journal:  Am J Public Health       Date:  1996-12       Impact factor: 9.308

9.  Hepatotoxicity associated with the new antidepressants.

Authors:  Alfonso Carvajal García-Pando; Javier García del Pozo; Ana Sánchez Sánchez; Martín Alfonso Velasco; Ana María Rueda de Castro; M Isabel Lucena
Journal:  J Clin Psychiatry       Date:  2002-02       Impact factor: 4.384

10.  Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.

Authors:  G M McQuillan; P J Coleman; D Kruszon-Moran; L A Moyer; S B Lambert; H S Margolis
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

View more
  5 in total

1.  PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.

Authors:  Debbie L Seem; Ingi Lee; Craig A Umscheid; Matthew J Kuehnert
Journal:  Public Health Rep       Date:  2013-07       Impact factor: 2.792

Review 2.  Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness.

Authors:  Ellen M Janssen; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Gen Hosp Psychiatry       Date:  2015-03-14       Impact factor: 3.238

3.  Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care.

Authors:  Lisa I Backus; Pamela S Belperio; Timothy P Loomis; Larry A Mole
Journal:  Am J Public Health       Date:  2014-09       Impact factor: 9.308

4.  Differences in substance-related risk behavior between dual and triple diagnosed severely mentally ill adults.

Authors:  Michelle Decoux Hampton; Linda Chafetz; Carmen Portillo
Journal:  Ment Health Subst Use       Date:  2011-11-29

5.  Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York City.

Authors:  S Amesty; D C Ompad; S Galea; C M Fuller; Y Wu; B Koblin; D Vlahov
Journal:  J Community Health       Date:  2008-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.